Oz Azam (L) and Carl June
April 25, 2022 06:50 AM EDTUpdated 04:17 PM
R&D
Cell/Gene Tx

New pa­per sheds fresh light on Tmu­ni­ty's high-pro­file CAR-T deaths

Jason Mast

Editor

The in­dus­try-wide ef­fort to push CAR-T ther­a­pies — wild­ly ef­fec­tive in sev­er­al blood can­cers — in­to sol­id tu­mors took a hit last year when Tmu­ni­ty, a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times